|
gptkbp:instanceOf
|
gptkb:vaccine
gptkb:protein_subunit_vaccine
|
|
gptkbp:adjuvant
|
gptkb:Matrix-M
|
|
gptkbp:administeredBy
|
adults
over 40 countries
adolescents (in some countries)
|
|
gptkbp:antigen
|
gptkb:SARS-CoV-2_spike_protein
|
|
gptkbp:approvedBy
|
2021
|
|
gptkbp:approvedForAgeGroup
|
adults
|
|
gptkbp:ATCCode
|
gptkb:J07BX23
|
|
gptkbp:boosterRecommended
|
yes
|
|
gptkbp:brand
|
gptkb:Covovax
gptkb:Nuvaxovid
|
|
gptkbp:clinicalTrialPhase
|
gptkb:Australia
gptkb:India
gptkb:Mexico
gptkb:South_Africa
gptkb:United_Kingdom
gptkb:United_States
Phase 3
|
|
gptkbp:contains
|
gptkb:SARS-CoV-2_spike_protein
gptkb:Matrix-M_adjuvant
|
|
gptkbp:developedBy
|
gptkb:Novavax
|
|
gptkbp:dosageSchedule
|
two doses, 21 days apart
|
|
gptkbp:efficacyAgainstSymptomaticCOVID19
|
~90%
|
|
gptkbp:emergencyServices
|
gptkb:India
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkb:United_States_Food_and_Drug_Administration
|
|
gptkbp:excludes
|
gptkb:virus
gptkb:gene
live virus
|
|
gptkbp:manufacturer
|
gptkb:Novavax
gptkb:Serum_Institute_of_India
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:shelfLife
|
up to 9 months at 2–8°C
|
|
gptkbp:sideEffect
|
fever
nausea
fatigue
headache
joint pain
muscle pain
chills
injection site pain
swelling at injection site
redness at injection site
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:technology
|
recombinant nanoparticle
|
|
gptkbp:usedAsBooster
|
yes
|
|
gptkbp:WHOEmergencyUseListing
|
December 2021
|
|
gptkbp:bfsParent
|
gptkb:Novavax
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NVX-CoV2373
|